Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Alcon ( (CH:ALC) ) is now available.
On February 24, 2026, Alcon filed a Form 6-K with the U.S. SEC, attaching glossy pages of its 2025 Annual Report, which detail a year the company describes as transformative despite tariff pressures and difficult market conditions. The report highlights strong innovation across its Surgical and Vision Care franchises, including a next-generation Unity VCS/CS ophthalmic surgical platform, enhancements to its PanOptix trifocal IOL line, a new non-invasive glaucoma laser therapy, a first weekly replacement contact lens and TRYPTYR, its first post-spin ophthalmic pharmaceutical, all aimed at expanding its addressable eye-care market and reinforcing competitive positioning.
The company reports 2025 net sales of $10.3 billion, up 5% as reported (4% constant currency), diluted EPS of $1.98, core diluted EPS of $3.07, and $1.7 billion in free cash flow, allowing $848 million in capital returns through buybacks and dividends, which underscores healthy cash generation and disciplined capital deployment. Alcon also advanced strategic M&A through acquisitions such as LumiThera and a majority stake in Aurion Biotech to build capabilities in retinal and corneal therapies, strengthened governance with the appointment of healthcare-technology executive Deborah Di Sanzo to the board, and achieved its 2025 social impact goals by improving vision for more than 5 million cataract patients in low- and middle-income countries and screening over 150,000 children, signaling a broader sustainability and access-to-care agenda alongside its growth strategy.
The most recent analyst rating on (CH:ALC) stock is a Buy with a CHF91.00 price target. To see the full list of analyst forecasts on Alcon stock, see the CH:ALC Stock Forecast page.
More about Alcon
Alcon Inc., based in Fribourg, Switzerland, is a global eye-care company focused on surgical ophthalmology and vision care products. Its portfolio spans cataract and vitreoretinal surgical platforms, intraocular lenses, contact lenses, ophthalmic pharmaceuticals, and related technologies serving eye-care professionals and patients worldwide.
Average Trading Volume: 1,096,585
Technical Sentiment Signal: Sell
Current Market Cap: CHF31.5B
Find detailed analytics on ALC stock on TipRanks’ Stock Analysis page.